Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients

Clinical Biochemistry

Volumn 45, Issue 7-8, 2012, Pages 575-581

  Tomasetti, Marco ^a   Staffolani, Sara ^a   Nocchi, Linda ^a   Neuzil, Jiri ^b,c   Strafella, Elisabetta ^a   Manzella, Nicola ^a   Mariotti, Laura ^a   Bracci, Massimo ^a   Valentino, Matteo ^a   Amati, Monica ^a   Santarelli, Lory ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b GRIFFITH UNIVERSITY   (Australia)

^c INSTITUTE OF BIOTECHNOLOGY   (Czech Republic)

Author keywords

Absolute qRT PCR; Circulating miR 126; Clinic validation; Malignant mesothelioma; Non small cell lung cancer; Relative qRT PCR

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 126; UNCLASSIFIED DRUG;

ACCURACY; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MALE; MESOTHELIOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERUM; STATISTICAL ANALYSIS; VALIDATION STUDY;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MESOTHELIOMA; MICRORNAS; MIDDLE AGED; PROGNOSIS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84860142623     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.02.009     Document Type: Article

References (38)

1. Duffy M.J. Role of tumor markers in patients with solid cancers: a critical review. Eur J Intern Med 2007, 18:175-184.
2. Tomasetti M., Amati M., Santarelli L., Alleva R., Neuzil J. Malignant mesothelioma: biology, diagnosis and therapeutic approaches. Curr Mol Pharmacol 2009, 2:190-206.
3. Etzioni R., Urban N., Ramsey S., McIntosh M., Schwartz S., Reid B., et al. The case for early detection. Nat Rev Cancer 2003, 3:243-252.
4. Sugarbaker D.J., Flores R.M., Jaklitsch M.T., Richards W.G., Strauss G.M., Corson J.M., et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999, 117:54-63.
5. Galasso M., Sana M.E., Volinia S. Non-coding RNAs: a key to future personalized molecular therapy?. Genome Med 2010, 2:12.
6. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
7. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008, 105:10513-10518.
8. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006.
9. Guled M., Lahti L., Lindholm P.M., Salmenkivi K., Bagwan I., Nicholson A.G., et al. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma - an miRNA microarray analysis. Genes Chromosomes Cancer 2009, 48:615-623.
10. Busacca S., Germano S., De Cecco L., Rinaldi M., Comoglio F., Favero F., et al. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol 2010, 42:312-319.
11. Gee G.V., Koestler D.C., Christensen B.C., Sugarbaker D.J., Ugolini D., Ivaldi G.P., et al. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. Int J Cancer 2010, 127:2859-2869.
12. Ivanov S.V., Goparaju C.M., Lopez P., Zavadil J., Toren-Haritan G., Rosenwald S., et al. Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem 2010, 285:22809-22817.
13. Santarelli L., Strafella E., Staffolani S., Amati M., Emanuelli M., Sartini D., et al. MiR-126 as a promising marker for early detection of malignant mesothelioma: association with soluble mesothelin-related peptides. PLoS One 2011, 6:e18232.
14. Huang Z., Huang D., Ni S., Peng Z., Sheng W., Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010, 127:118-126.
15. Ng E.K., Chong W.W., Jin H., Lam E.K., Shin V.Y., Yu J., et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009, 58:1375-1381.
16. Roa W., Brunet B., Guo L., Amanie J., Fairchild A., Gabos Z., et al. Identification of a new microRNA expression profile as a potential cancer screening tool. Clin Invest Med 2010, 33:E124.
17. Gee H.E., Buffa F.M., Camps C., Ramachandran A., Leek R., Taylor M., et al. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer 2011, 104:1168-1177.
18. Zhu W., Qin W., Atasoy U., Sauter E.R. Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes 2009, 2:89.
19. Moltzahn F., Olshen A.B., Baehner L., Peek A., Fong L., Stöppler H., et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 2011, 71:550-560.
20. Kroh E.M., Parkin R.K., Mitchell P.S., Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010, 50:298-301.
21. Bianchi F., Nicassio F., Marzi M., Belloni E., Dall'olio V., Bernard L., et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 2011, 3:495-503.
22. Peltier H.J., Latham G.J. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 2008, 14:844-852.
23. McDonald J.S., Milosevic D., Reddi H.V., Grebe S.K., Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 2011, 57:833-840.
24. Chang K.H., Mestdagh P., Vandesompele J., Kerin M.J., Miller N. MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer. BMC Cancer 2010, 10:173.
25. Peltier H.J., Latham G.J. RNA. Normalisation of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 2008, 14:844-852.
26. Calin G.A., Croce C.M. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006, 66:7390-7394.
27. Song J., Bai Z., Han W., Zhang J., Meng H., Bi J., et al. Identification of Suitable Reference Genes for qPCR Analysis of Serum microRNA in Gastric Cancer Patients. Dig Dis Sci 2011, 10.1007/s10620-011-1981-7.
28. Zhu H.T., Dong Q.Z., Wang G., Zhou H.J., Ren N., Jia H.L., et al. Identification of suitable reference genes for qRT-PCR analysis of circulating microRNAs in hepatitis B virus-infected patients. Mol Biotechnol 2012, 50:49-56.
29. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3. (RESEARCH0034).
30. Derveaux S., Vandesompele J., Hellemans J. How to do successful gene expression analysis using real-time PCR. Methods 2010, 50:227-230.
31. Wotschofsky Z., Meyer H.A., Jung M., Fendler A., Wagner I., Stephan C., et al. Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. Anal Biochem 2011, 417:233-241.
32. Février B., Raposo G. Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol 2004, 16:415-421.
33. Song J.J., Liu J., Tolia N.H., Schneiderman J., Smith S.K., Martienssen R.A., et al. The crystal structure of the Argonaute2 PAZ domain reveals an RNA binding motif in RNAi effector complexes. Nat Struct Biol 2003, 10:1026-1032.
34. Arroyo J.D., Chevillet J.R., Kroh E.M., Ruf I.K., Pritchard C.C., Gibson D.F., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 2011, 108:5003-5008.
35. Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977, 37:646-650.
36. Zhu N., Zhang D., Xie H., Zhou Z., Chen H., Hu T., Bai Y., Shen Y., Yuan W., Jing Q., Qin Y. Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2. Mol Cell Biochem 2011, 351:157-164.
37. Yanaihara N., Caplen N., Bowman E., Seike M., Kumamoto K., Yi M., Stephens R.M., Okamoto A., Yokota J., Tanaka T., Calin G.A., Liu C.G., Croce C.M., Harris C.C. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
38. Lin Q., Mao W., Shu Y., Lin F., Liu S., Shen H., Gao W., Li S., Shen D.J. A cluster of specified microRNAs in peripheral blood as biomarkers for metastatic non-small-cell lung cancer by stem-loop RT-PCR. Cancer Res Clin Oncol 2012, 138:85-93.